LUPKYNIS Associated with a Statistically Significant 53% Reduction in Risk of Renal-Related Event or Death
— New Analysis of the AURORA 1 Phase 3 Study Presented at EULAR 2026 Congress — ROCKVILLE, Md. & EDMONTON, Alberta — Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced that a new analysis of the AURORA 1 Phase 3 study of LUPKYNIS® in the treatment of lupus nephritis is being presented at the European Alliance […]
Original Source
Read the full article at Financialpost →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.